On June 15, 2021, RayzeBio, Inc., a company discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, announced a $108 million Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X. Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others. With over $258 million of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

The Wilson Sonsini Goodrich & Rosati team that advised RayzeBio on patent matters related to the transaction was led by Ying Chen and included Michael Hostetler.

For more information, please see RayzeBio's press release. Further coverage can be found at Fierce Biotech.